Foghorn Therapeutics (FHTX) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 226.92%.
- Foghorn Therapeutics' EBIT Margin rose 785600.0% to 226.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 352.87%, marking a year-over-year increase of 552700.0%. This contributed to the annual value of 454.31% for FY2024, which is 1383800.0% down from last year.
- According to the latest figures from Q3 2025, Foghorn Therapeutics' EBIT Margin is 226.92%, which was up 785600.0% from 279.17% recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' EBIT Margin registered a high of 97.73% during Q3 2023, and its lowest value of 64051.22% during Q3 2021.
- In the last 5 years, Foghorn Therapeutics' EBIT Margin had a median value of 572.42% in 2023 and averaged 4825.42%.
- Per our database at Business Quant, Foghorn Therapeutics' EBIT Margin plummeted by -537221700bps in 2021 and then soared by 636252500bps in 2022.
- Over the past 5 years, Foghorn Therapeutics' EBIT Margin (Quarter) stood at 3938.57% in 2021, then skyrocketed by 81bps to 762.09% in 2022, then skyrocketed by 42bps to 441.29% in 2023, then plummeted by -90bps to 840.51% in 2024, then skyrocketed by 73bps to 226.92% in 2025.
- Its EBIT Margin stands at 226.92% for Q3 2025, versus 279.17% for Q2 2025 and 384.96% for Q1 2025.